Addex Therapeutics Emerges From Under The Radar

Having had to retrench after a financial crisis four years ago, Swiss biotech Addex Therapeutics has been focusing on its in-house platform around allosteric modulation. CEO Tim Dyer speaks to Scrip in a video interview recorded at Biotech Showcase.